Based on 1 Customer Validation
Stemregenin 1 (SR1) (GMP) is a GMP-grade Stemregenin 1 (HY-15001). GMP-grade small molecules can be used as adjuvants in cell therapy. Stemregenin 1 is a potent aryl hydrocarbon receptor (AhR) antagonist with an IC50 of 127 nM. Stemregenin 1 (GMP) can competitively bind to AhR and inhibit its nuclear translocation, inhibiting osteoclastogenesis and promoting hematopoietic progenitor cell expansion by blocking the AhR-c-src-NF-κB/p-ERK MAPK-NFATc1 signaling pathway. Stemregenin 1 (GMP) can be used for the study of osteoporosis, in vitro expansion of hematopoietic stem cells, and the study of the mechanism of bone metabolic diseases.
For research use only. We do not sell to patients.
- CAS No.: 1227633-49-9
- Formula: C24H23N5OS
- Molecular Weight:429.54
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
IC50: 127 nM (AhR)[4]
Stemregenin 1 (GMP) (1, 5, 10 μM; 7 days) promotes CD34+ cell expansion and enhance colony formation ability in human embryonic stem cell-derived hematopoietic progenitor cell experiments in a concentration-dependent manner, but inhibits cell proliferation at 10 μM[1].
Stemregenin 1 (GMP) (0.75 μM; 7 days) combined with DMOG increases the proportion of primitive hematopoietic subsets and improves the number of long-term colony-forming units in CD34+ umbilical cord blood cell experiments[2].
Stemregenin 1 (GMP) (3, 6, 8, 10 μM; 4-7 days) inhibits RANKL-induced osteoclast differentiation in bone marrow macrophage experiments, reduces the expression of genes such as NFATc1 and ACP5, and F-actin ring formation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BMMs, hESC-derived hematopoietic progenitors, CD34+ cord blood cells
-
Concentration:0-10 μM
-
Incubation Time:48-96 h for BMMs; 7 days for others
-
Result:Hed no cytotoxicity in BMMs at ≤10 μM, and maintained CD34+ cells viability without significant loss at 0.75 μM.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice (female, 8 weeks old, 20-25 g) with ovariectomized (OVX) osteoporosis model[3]
-
Dosage:2.5 mg/kg
-
Administration:Intraperitoneal injection, once every 3 days, for 42 days
-
Result:Reversed OVX-induced bone loss, as shown by micro-CT analysis demonstrating increased trabecular bone volume/total volume (BV/TV).
Improved bone mineralization.
Serum markers of bone resorption were reduced, and bone formation markers were enhanced.
Chemical Information
-
CAS No. 1227633-49-9
-
Appearance Solid
-
Molecular Weight 429.54
-
Formula C24H23N5OS
-
Color Off-white to yellow
-
SMILES
CC(C)N1C2=NC(C3=CSC4=C3C=CC=C4)=NC(NCCC5=CC=C(O)C=C5)=C2N=C1
-
Synonyms
SR1 (GMP)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Tao L, et al. StemRegenin 1 selectively promotes expansion of Multipotent Hematopoietic Progenitors derived from Human Embryonic Stem Cells. J Stem Cells Regen Med. 2017 Dec 18;13(2):75-79. [Content Brief]
[2]. Jackson CS, et al. Targeting the aryl hydrocarbon receptor nuclear translocator complex with DMOG and Stemregenin 1 improves primitive hematopoietic stem cell expansion. Stem Cell Res. 2017 May;21:124-131. [Content Brief]
[3]. Zhou S, et al. StemRegenin 1 attenuates the RANKL-induced osteoclastogenesis via inhibiting AhR-c-src-NF-κB/p-ERK MAPK-NFATc1 signaling pathway. iScience. 2024 Apr 6;27(5):109682. [Content Brief]
[4]. Boitano AE, et al. Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells. Science. 2010 Sep 10;329(5997):1345-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz